

## **CURRICULUM VITAE**

### **RUXANDRA DOBRESCU**

**Medic primar endocrinolog. Cercetator stiintific.**

#### **STUDII:**

- Studii universitare de doctorat, 10.2018-prezent: Universitatea de Medicina si Farmacie “Carol Davila” Bucuresti, Scoala doctorala, “Markeri de diagnostic si prognostic in cancerul tiroidian diferentiat”.
- 06.2016: Examen medic primar promovat cu media 9.89.
- 2007-2011: Programul de pregatire in rezidentiat, Endocrinologie, Bucuresti – examenul de medic specialist promovat in sesiunea Octombrie 2011 cu media 9.81.
- 17.09-14.12.2010: Stagiu de pregatire in cadrul Oxford Center for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, sub indrumarea Prof John Wass.
- 2000-2006: Universitatea de Medicina si Farmacie “Carol Davila” Bucuresti
- 04.2002-08.2002: Grant Erasmus– Oxford University, Great Britain
- 1996-2000: Colegiul National Sf Sava, Bucuresti

#### **EXPERIENTA PROFESIONALA:**

- 09.2014 – prezent: Centrul Medical Panduri. Medic specialist/ primar endocrinolog.
- 18.01.2016 – 31.12.2021: Cercetator stiintific, Medic primar endocrinolog in cadrul Laboratorului de Cercetare Stiintifica, Institutul National de Endocrinologie “C.I. Parhon”, Bucuresti
- 01.01.2012 – 17.01.2016: Institutul “C.I. Parhon”, Bucuresti. Medic specialist endocrinolog. Subinvestigator in studiul SELECT: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I - Refractory Differentiated Thyroid Cancer
- 02.2012 – 11.2014: Centrul Medical Sphera. Medic specialist endocrinolog.
- 17.09.2010 – 14.12.2010: Oxford Center for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford. Stagiu de pregatire, observator clinic.
- 01.2007 – 12.2011: Medic rezident endocrinolog, Sp Floreasca, Bucuresti. Stagii de endocrinologie desfasurate in cadrul Institutului National de Endocrinologie “C.I. Parhon”, Bucuresti.
- 19.11.2006: Examenul National de Rezidentiat. Punctaj 879, locul 33 din 2903 candidati.

### **PROIECTE DE CERCETARE, STUDII CLINICE, ACTIVITATE DIDACTICA:**

- "Molecular markers as predictors of post-therapeutic evolution and prognosis in the management of differentiated thyroid cancer" - GENITIR, PCCA2 nr 135/2012, UEFISCDI
- SELECT trial: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I - Refractory Differentiated Thyroid Cancer (SELECT, EISAI protocol Nb. E7080-G000-303) – Subinvestigator
- E7080-G000-211 trial: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects with <sup>131</sup>I-Refractory Differentiated Thyroid Cancer – Subinvestigator
- EXAMINER Clinic trial. A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients.
- ENDODIAB - Proiectul “Creșterea competenței profesionale a specialiștilor din sectorul medical în implementarea programelor naționale din domeniul endocrinologiei și diabetului zaharat” - cursuri de formare pentru specialiști de laborator.

### **MEMBRU AL ASOCIATIILOR PROFESIONALE:**

- Membru al Societatii Romane de Endocrinologie
- Membru al Societatii Romane de Psihoneuroendocrinologie
- Membru al Societatii Europene de Endocrinologie
- Membru al Societatii Britanice de Endocrinologie
- Membru al Asociatiei Europene de Tiroida

### **REVIEWER**

- Cancer Biomarkers
- Acta Endocrinologica Bucuresti
- Romanian Journal of Internal Medicine

### **INDICATORI BIBLIOMETRICI:**

**Indice Hirsh (Web of Science): 5**

**Numar citari: 62**

## CELE MAI IMPORTANTE PUBLICATII STIINTIFICE 2015-2022:

### Capitole de carte:

1. Papillary, follicular and anaplastic thyroid carcinoma and lymphoma. **Dobrescu R**, Badiu C. În Oxford Textbook of Endocrinology and Diabetes 3rd Edition, 2022. ISBN: 9780198870197.
2. Efectul pandemiei SARS-CoV-2 asupra managementului afecțiunilor tiroidiene benigne sau maligne. **Dobrescu R**, Stănescu L, Chiriac I, Stancu AM, Badiu C. În Antropologie și tradiții. Colecția Zilele Rainer, 2022. ISBN 978-973-27-3200-7.
3. Patologia tiroidiană în România – de la gușa endemică la secvențierea genetică în cancerul tiroidian. **Dobrescu R**, Chiriac I, Gheorghiu M, Badiu C. În Antropologie și tradiții. Colecția Zilele Rainer, 2021. ISBN 978-973-27-3376-9.

### Articole științifice:

1. Matrix metalloproteinase-9 (MMP-9) promoter -1562 C/T functional polymorphism is associated with an increased risk to develop micropapillary thyroid carcinoma. **Dobrescu R**; Schipor S; Manda D; Caragheorgheopol A; Badiu C. Cancer Biomarkers, 2022.
2. What is Hidden in a Cystic Lesion after Extensive Surgery for Medullary Thyroid Carcinoma? **Dobrescu R**, Stanescu B, Ioachim D, Badiu C. Acta Endo (Buc) 2021 17(2): 280-281 doi: 10.4183/aeb.2021.280.
3. Serum MMP-9 can help identify patients with papillary thyroid cancer at high risk of persistent disease: value and limitations of a potential marker of neoplasia. **Dobrescu R**, Picu C, Caragheorgheopol A, Manda D, Ioachim D, Goldstein A, Badiu C. Cancer Biomarkers, Cancer Biomarkers 2020;29(3):337-346.
4. Actualities in genetics of differentiated thyroid cancer. **Dobrescu R**, Badiu C. Acta Endocrinologica, Jan-Mar 2020;16(1):118-120. doi: 10.4183/aeb.2020.118.
5. Alterations of Regulatory Factors and DNA Methylation Pattern in Thyroid Cancer. Iancu IV, Botezatu A, Plesa A., Huica I., Fudulu A., Albulescu A., Bostan M., Mihaila M., Grancea C., Manda D., **Dobrescu R.**, Vladoiu S., Anton G., Badiu C. Cancer Biomarkers, vol. 28, no. 2, pp. 255-268, 2020.
6. Telomeres biology involvement in thyroid neoplasia: from aging clock to aggressive cancers. Badiu C, **Dobrescu R**. Toxicol Lett. 2019;314:S29-S30.
7. Methylation of tumour suppressor genes associated with thyroid cancer. Botezatu A, Iancu IV, Plesa A, Manda D, Popa O, Bostan M, Mihaila M, Albulescu A, Fudulu A, Vladoiu S, Huica I, **Dobrescu R**, Anton G, Badiu C. Cancer Biomark. 2019;25(1):53-65.
8. Novel Markers for Early Diagnosis and Prognostic Classification in Medullary Thyroid Carcinoma. Baetu M, **Dobrescu R**. Acta Endo (Buc) 2017, 13 (4): 519-522.

9. An Expanding Class in the Treatment of Thyroid Cancer: Thyrosin Kinase Inhibitors. **Dobrescu R**, Badiu C. Acta Endocrinologica, vol XI, no 4, p 536-539, 2015.
10. Growth Hormone Deficiency in Adults Impacts Left Ventricular Mechanics: A Two-Dimensional Speckle-Tracking Study. Mihaila S, Mincu RI, Rimbas RC, Dulgheru RE, **Dobrescu R**, Magda SL, Badiu C, Vinereanu D. Canadian Journal of Cardiology, June 2015, vol 31, Issue 6, 752-759.

**Lucrari prezentate la congrese nationale si internationale (lucrari selectionate):**

- 06.2022: BRAF V600E and TERT promoter mutations in differentiated thyroid cancer in Romania - clinical and pathological correlations. Dobrescu R, Schipor S, Muresan A, Ioachim D, Goldstein A, Manda D, Vladoiu S, Badiu C. The 30th National Congress of the Romanian Endocrine Society, Bucharest, Romania.
- 02.2022: Differentiated thyroid cancer in pregnancy. Dobrescu R, Bojoga A, Badiu C. AECR Symposium, Online Meeting.
- 04.2020: MMP-9 1562 C/T polymorphism may be associated with an increased susceptibility to develop micropapillary thyroid cancer but not more advanced tumours. Dobrescu R, Schipor S, Picu C, Manda D, Caragheorghopol A, Badiu C. European Congress of Endocrinology, accepted.
- 11.2019: Targeted therapies in advanced differentiated thyroid cancer: efficacy, quality of life, perspectives. Dobrescu R, Baetu M, Dyachenko K, Hortopan D, Dumitrascu A, Goldstein A, Badiu C. The 22-nd Symposium of the Romanian Society of PsychoNeuroEndocrinology, Timisoara, Romania.
- 09.2019: Telomerase biology involvement in thyroid neoplasia: from aging clock to aggressive cancers. Badiu C, **Dobrescu R**. The 55-th Congress of the European Societies of Toxicology, Helsinki, Finland.
- 09.2019: Value of serum MMP-9 as a circulating marker in thyroid cancer is highly dependent on sampling and collection conditions. **Dobrescu R**, Picu C, Caragheorghopol A, Manda D, Ioachim D, Goldstein A, Badiu C. European Thyroid Association Meeting, Budapest, Hungary.
- 09.2019: Pre-surgical molecular diagnosis of thyroid nodules. **Dobrescu R**, Badiu C, Romanian Association of Clinical Endocrinology, Sinaia, Romania – *The AECR prize*.
- 05.2019: Value and limitation of serum MMP-9 in thyroid nodular disease. **Dobrescu R**, Picu C, Manda D, Caragheorghopol A, Badiu C. The 21st European Congress of Endocrinology, 2019, Lyon, France.
- 10.2018: Clinical variability, diagnostic and therapeutic challenges in medullary thyroid carcinoma. Al 6-lea Congres National de Neuroendocrinologie, Bucuresti. **Dobrescu R**, Baetu M, Dumitrascu A, Ioachim D, Caragheorghopol A, Badiu C – *3rd prize of the Romanian Neuroendocrinology Society*

- 09.2018: The thyroid - beyond the anatomo-pathologic exam. Is immunohistochemistry a useful ancillary technique in the diagnosis? The XIII-th Congress of the Romanian Clinical Endocrinology Association. Stancu C, **Dobrescu R**, Ioachim D, Manda D, Caragheorgheopol A – *The AECR prize*
- 06.2018: Medullary Thyroid Carcinoma – a change of paradigm? **Dobrescu R**, Baetu M, Ioachim D, Caragheorgheopol A, Badiu C. The XXVI–th National Endocrinology Congress, Sibiu, Romania.
- 06.2018: Galectin-3 in the diagnosis and prognosis of differentiated thyroid cancer. **Dobrescu R**, Picu C, Stancu C, Ioachim D, Manda D, Badiu C, Caragheorgheopol A. The XXVI–th National Endocrinology Congress, Sibiu, Romania
- 06.2018: Utility of immunohistochemical markers in the field of thyroid pathology. Stancu C, **Dobrescu R**, Picu C, Muresan A, Padure A, Terzea D, Ioachim D, Manda D, Caragheorgheopol A. The XXVI–th National Endocrinology Congress, Sibiu, Romania
- 06.2018: Cut-off values for basal and calcium stimulated calcitonin for medullary thyroid carcinoma diagnosis. Băetu M, Gheorghiu CA, Corneci C, Smarandache R, Ioachim D, Caragheorgheopol A, **Dobrescu R**, Corin Badiu. The XXVI–th National Endocrinology Congress, Sibiu, Romania
- 06.2018: Multiple endocrine neoplasia syndromes - a genetic approach. Păun DL, Mureșan A, Baciuc I, Braha E, Dragomir A, Petriș R, Jercălău S, Grigorie D, Ghervan C, Georgescu C, Ilie I, Creț V, Milos I, Plăcintă S, Radu CP, Găleşanu C, Carsote ML, Tupea C, Gherlan I, Gheorghiu M, **Dobrescu R**, Băetu M, Manda D, Poiană C, Badiu C, Radian S. The XXVI–th National Endocrinology Congress, Sibiu.
- 06.2018: Endocrine pathology in patients with neurofibromatosis type 1. Stancu AM, Dyachenko K, **Dobrescu R**, Badiu C. The XXVI–th National Endocrinology Congress, Sibiu, Romania
- 05.2018: RET exon 11 genotype in medullary thyroid cancer. Muresan A, Radian S, Ghervan C, Gheorghiu M, Paun D, Baciuc I, Ioachim D, Padure A, **Dobrescu R**, Manda D & Badiu C. 20th European Congress of Endocrinology, 19-22 May 2018, Barcelona, Spain.
- 05.2018: Thresholds of basal and calcium stimulated calcitonin for diagnosis of medullary thyroid carcinoma. Baetu M, Gheorghiu C, Corneci C, Ioachim D, Caragheorgheopol A, **Dobrescu R**, Badiu C. 20th European Congress of Endocrinology, 19-22 May 2018, Barcelona, Spain.
- 10.2017: Tyrosine kinase inhibitors in the treatment of thyroid cancer: at the border between guidelines and personalized treatment. Badiu C, **Dobrescu R**. The 21st National Neuroendocrinology Symposium, Iasi, Romania.
- 10.2017: Evaluation of patients with medullary thyroid carcinoma followed up in a tertiary endocrinology center. Radian S, Dima M, Baciuc I, Trifanescu R, Galoiu S, Niculescu D, Capatina C, **Dobrescu R**, Muresan A, Stanescu B, Ghemigian M, Ioachim D, Badiu C, Poiana C. The 21st National Neuroendocrinology Symposium, Iasi, Romania.

- 09.2017: Dynamic of serum biomarkers gal-3, mmp-2 and mmp-9 in thyroid tumor disease in relation to surgery. **Dobrescu R**, Schipor S, Picu C, Manda D, Badiu C, Caragheorgheopol A. 40-th Annual Meeting of the ETA, Belgrade, Serbia.
- 09.2017: Association between seric levels of MMP-9, the MMP-9-1562 C/T polimorphism and papillary thryoid carcinoma, **Dobrescu R**, Picu C, Schipor S, Padure A, Parvu L, Ioachim D, Giulea C, Badiu C, Caragheorgheopol A. The XII-th Congress of the AECR, Tulcea, Romania.
- 07.2017: Challenging management of malignant struma ovarii, follicular thyroid carcinoma and Graves' disease. Goldstein H; **Dobrescu R**; Coles D; Goldstein D; Gherlan I; Chiriac IA; Badiu C; Ioachim D; Terzea D; Voicu G; Goldstein A. The 3<sup>rd</sup> World Congress on Thyroid Cancer. Boston, United States.
- 05.2017: Association between preoperative serum MMP-9 and histopathological features of thyroid tumors. **Dobrescu R**, Picu C, Schipor S, Padure A, Parvu L, Manda D, Ioachim D, Badiu C & Caragheorgheopol A. 19th European Congress of Endocrinology, 20-23 May 2017, Lisbon, Portugal.
- 05.2017: Stimulated calcitonin levels as a predictor of medullary thyroid cancer. Gheorghiu C, Corneci C, Jercalau S, **Dobrescu R**, Mihai D, Badiu C. 19th European Congress of Endocrinology, 20-23 May 2017, Lisbon, Portugal.
- 09.2016: Clinical variability and translational approach in medullary thryoid carcinoma. Badiu C, **Dobrescu R**, Ioachim D, Baciu I, Gheorghiu M. The 17-th International Congress of Endocrinology, Beijing, China.
- 06.2016: Galectin-3 and clinical evolution of differentiated thryoid cancer – Preliminary results of the GENITIR study. **Dobrescu R**, Schipor S, Picu C, Manda D, Niculescu AM, Ioachim D, Goldstein A, Caragheorgheopol A, Badiu C. The XXIV–th National Congress of Endocrinology, Brasov, Romania.
- 05.2016: Does serum Galectin-3 add value in thyroid cancer diagnosis? **Dobrescu R**, Schipor S, Manda D, Picu C, Giulea C, Niculescu AM, Badiu C, Caragheorgheopol A. The 18-th European Congress of Endocrinology, 2016, Munchen, Germany.
- 11.2015: Diagnostic and therapeutic challenges in medullary thryoid carcinoma. **Dobrescu R**, Badiu I, Ioachim D, Badiu C. British Endocrine Society Meeting 2015, Edinburgh, Marea Britanie.